Bronchiectasis patients and caregivers are urged to share their stories as soon as possible!
On March 11, the Institute for Clinical and Economic Review (ICER) announced a review of brensocatib for the treatment of non-cystic fibrosis bronchiectasis (NCFB). Brensocatib was shown in clinical trials to reduce frequency of exacerbations and slow the decline of lung function in patients with bronchiectasis.
ICER strives to better understand the lived experience of people with NCFB, such as the impact on daily life, impact on caregivers, experience with prior or current therapies, and hopes for a new treatment.
With this review, they hope to reflect the priorities and outcomes of importance to the patient community as what guides their approach to this process, with a stated goal of promoting fair pricing and access to care.
Currently, ICER is engaged in the “scoping” phase of this process, where they try to determine what is most important to include in their report about the treatment and the patient population who would be served by it. This scoping phase will conclude on Monday, March 31st.
We urge bronchiectasis patients and caregivers to share your stories with ICER, so they gain valuable insights from the patient perspective into the physical, emotional, social, economic, and other impact of bronchiectasis. You may submit your story regardless of whether you also have a lung infection at the moment – ICER should understand the impact and burden of bronchiectasis from as many perspectives as possible.
Click here to share your story with ICER using their online form.
Click here to see a PDF preview of the Share Your Story form – Patient View.
Click here to see a PDF preview of the Share Your Story form – Caregiver View.
